Teladoc Health Future Growth
Future criteria checks 0/6
Teladoc Health is forecast to grow earnings and revenue by 76.5% and 0.8% per annum respectively. EPS is expected to grow by 81.3% per annum. Return on equity is forecast to be -15.7% in 3 years.
Key information
76.5%
Earnings growth rate
81.3%
EPS growth rate
| Healthcare Services earnings growth | 28.1% |
| Revenue growth rate | 0.8% |
| Future return on equity | -15.7% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 02
Is Teladoc Health (NYSE:TDOC) A Risky Investment?
Oct 23Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition
Oct 13Teladoc Health, Inc. (NYSE:TDOC) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Sep 18Teladoc Health: Some Negative Things, But One Aspect That Makes Me Feel Positive
Sep 15Teladoc: Prospects Are Ready For Better Health
Sep 04Teladoc Post Q2 Earnings: Stick A Fork In This Stock - It's Nearly Done (For)
Aug 01Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)
Jul 22Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors
Jul 17Teladoc Health: Weight Loss Management Could Help
Jul 01Would Teladoc Health (NYSE:TDOC) Be Better Off With Less Debt?
Jun 04Teladoc: Stock Likely To Be Range Bound Until Guidance Is Revised Upwards
May 31Teladoc: Huge Execution Problem
Apr 27Teladoc: Improving Business Trends (Rating Upgrade)
Apr 17Teladoc: Management Has A Lot To Prove To Gain Investor Confidence
Mar 25Teladoc Health, Inc.'s (NYSE:TDOC) 25% Dip In Price Shows Sentiment Is Matching Revenues
Mar 10Teladoc Health: Another Bad Quarter, Another Wave Of Capitulation
Feb 21Teladoc Health: Weight Management Rescue
Jan 21Teladoc Health (NYSE:TDOC) Is Carrying A Fair Bit Of Debt
Jan 15When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?
Dec 12Teladoc Q3: Getting Stronger (Rating Upgrade)
Nov 29Teladoc Health, Inc.'s (NYSE:TDOC) Intrinsic Value Is Potentially 78% Above Its Share Price
Nov 22Teladoc Was Obliterated
Oct 25Is Teladoc Health (NYSE:TDOC) A Risky Investment?
Oct 11Teladoc: Broken Growth Story Deteriorates Further (Rating Downgrade)
Oct 02Teladoc Stock: A Hold Amid New Covid Wave
Sep 14Teladoc's Technical Decline Hints At A Buying Opportunity
Aug 28Is There An Opportunity With Teladoc Health, Inc.'s (NYSE:TDOC) 44% Undervaluation?
Aug 18Buy Teladoc: AI Will Likely Spur Healthcare Deflation
Aug 16Teladoc's Future: Virtual Healthcare, AI, And Valuation
Jul 28Teladoc And Microsoft's Expanded Strategic Partnership Is A Powerful AI Combo
Jul 21The Big Trends: New Frontiers in Healthcare
Jul 13
When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?
Jul 10Teladoc Health: Likely To Remain Out Of Favor
Jun 26Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors
Jun 25Here's Why Teladoc Health (NYSE:TDOC) Can Afford Some Debt
May 25Teladoc: BetterHelp Segment Margins Are Key
May 23Are Investors Undervaluing Teladoc Health, Inc. (NYSE:TDOC) By 20%?
May 06Is It Too Late To Consider Buying Teladoc Health, Inc. (NYSE:TDOC)?
Mar 10Teladoc Health Non-GAAP EPS of -$0.23 misses by $0.04, revenue of $637.7M beats by $4.33M
Feb 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,598 | -199 | 241 | 378 | 17 |
| 12/31/2025 | 2,539 | -158 | 214 | 363 | 24 |
| 12/31/2024 | 2,567 | -989 | 176 | 314 | 24 |
| 9/30/2024 | 2,590 | -982 | 207 | 338 | N/A |
| 6/30/2024 | 2,609 | -1,006 | 196 | 333 | N/A |
| 3/31/2024 | 2,619 | -233 | 200 | 346 | N/A |
| 12/31/2023 | 2,602 | -220 | 194 | 350 | N/A |
| 9/30/2023 | 2,580 | -4,002 | 112 | 285 | N/A |
| 6/30/2023 | 2,531 | -4,018 | 64 | 243 | N/A |
| 3/31/2023 | 2,471 | -7,054 | 47 | 234 | N/A |
| 12/31/2022 | 2,407 | -13,660 | 17 | 189 | N/A |
| 9/30/2022 | 2,323 | -9,860 | 65 | 207 | N/A |
| 6/30/2022 | 2,234 | -9,871 | 107 | 221 | N/A |
| 3/31/2022 | 2,144 | -6,904 | 99 | 180 | N/A |
| 12/31/2021 | 2,033 | -429 | 130 | 194 | N/A |
| 9/30/2021 | 1,862 | -812 | -54 | -4 | N/A |
| 6/30/2021 | 1,629 | -763 | -92 | -49 | N/A |
| 3/31/2021 | 1,367 | -655 | -102 | -65 | N/A |
| 12/31/2020 | 1,094 | -485 | -80 | -54 | N/A |
| 9/30/2020 | 867 | -110 | 59 | 80 | N/A |
| 6/30/2020 | 716 | -95 | 46 | 61 | N/A |
| 3/31/2020 | 606 | -98 | 19 | 31 | N/A |
| 12/31/2019 | 553 | -99 | 19 | 30 | N/A |
| 9/30/2019 | 520 | -105 | 4 | 14 | N/A |
| 6/30/2019 | 493 | -108 | 2 | 11 | N/A |
| 3/31/2019 | 457 | -103 | -8 | 1 | N/A |
| 12/31/2018 | 418 | -97 | -13 | -5 | N/A |
| 9/30/2018 | 372 | -117 | -22 | -15 | N/A |
| 6/30/2018 | 330 | -125 | N/A | -37 | N/A |
| 3/31/2018 | 280 | -115 | N/A | -36 | N/A |
| 12/31/2017 | 233 | -107 | N/A | -34 | N/A |
| 9/30/2017 | 194 | -77 | N/A | -35 | N/A |
| 6/30/2017 | 157 | -75 | N/A | -38 | N/A |
| 3/31/2017 | 139 | -75 | N/A | -47 | N/A |
| 12/31/2016 | 123 | -74 | N/A | -52 | N/A |
| 9/30/2016 | 108 | -75 | N/A | -57 | N/A |
| 6/30/2016 | 96 | -58 | N/A | -59 | N/A |
| 3/31/2016 | 88 | -61 | N/A | -54 | N/A |
| 12/31/2015 | 77 | -58 | N/A | -47 | N/A |
| 9/30/2015 | 68 | -50 | N/A | -39 | N/A |
| 6/30/2015 | 59 | -42 | N/A | -24 | N/A |
| 3/31/2015 | 51 | -29 | N/A | -19 | N/A |
| 12/31/2014 | 44 | -20 | N/A | -11 | N/A |
| 12/31/2013 | 20 | -10 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TDOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TDOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TDOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TDOC's revenue (0.8% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: TDOC's revenue (0.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TDOC is forecast to be unprofitable in 3 years.